Cara Therapeutics (NASDAQ:CARA) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Several other analysts also recently weighed in on the company. Canaccord Genuity set a $25.00 price objective on Cara Therapeutics and gave the company a “buy” rating in a research report on Monday, November 20th. Scotiabank boosted their price objective on Cara Therapeutics from $31.00 to $31.50 and gave the company an “outperform” rating in a research report on Tuesday, October 17th. Janney Montgomery Scott upgraded Cara Therapeutics from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $27.00 to $21.00 in a research report on Monday. BMO Capital Markets reiterated a “market perform” rating and issued a $25.00 price objective on shares of Cara Therapeutics in a research report on Tuesday, November 7th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $17.00 price objective on shares of Cara Therapeutics in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Cara Therapeutics has a consensus rating of “Buy” and an average target price of $25.09.

Shares of Cara Therapeutics (NASDAQ CARA) opened at $14.48 on Tuesday. Cara Therapeutics has a 12-month low of $11.11 and a 12-month high of $28.50. The firm has a market capitalization of $472.17, a P/E ratio of -6.32 and a beta of 3.01.

In related news, CEO Derek T. Chalmers sold 12,500 shares of the company’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $15.00, for a total value of $187,500.00. Following the sale, the chief executive officer now directly owns 1,073,792 shares of the company’s stock, valued at $16,106,880. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Frederique Ph.D. Menzaghi sold 15,000 shares of the company’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $15.00, for a total value of $225,000.00. Following the completion of the sale, the senior vice president now directly owns 122,000 shares in the company, valued at $1,830,000. The disclosure for this sale can be found here. 7.50% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of CARA. Legal & General Group Plc grew its stake in Cara Therapeutics by 10.4% in the second quarter. Legal & General Group Plc now owns 7,167 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 678 shares during the period. Cetera Advisor Networks LLC purchased a new stake in Cara Therapeutics in the fourth quarter worth $125,000. MANA Advisors LLC purchased a new stake in Cara Therapeutics in the fourth quarter worth $125,000. Courier Capital LLC purchased a new stake in Cara Therapeutics in the fourth quarter worth $147,000. Finally, Fox Run Management L.L.C. purchased a new stake in Cara Therapeutics in the fourth quarter worth $157,000. 58.98% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Cara Therapeutics (CARA) Stock Rating Upgraded by ValuEngine” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/02/15/cara-therapeutics-cara-stock-rating-upgraded-by-valuengine.html.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.